481
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Modelling pharmaceutical price changes in Germany: a function of competition and regulation

Pages 4515-4526 | Published online: 02 Feb 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Junjie Liu, Liming Wang, Chenxi Liu & Xinping Zhang. (2017) Impact of price deregulation policy on the affordability of essential medicines for women’s health: a panel data analysis. Expert Review of Pharmacoeconomics & Outcomes Research 17:6, pages 625-631.
Read now

Articles from other publishers (12)

Reinhard Busse, Jonas Schreyögg, Oliver Tiemann, Bernhard Gibis, Ricarda Milstein, Matthias Bäuml, Jonas Müller, Helmut Hildebrandt, Oliver Gröne, Timo Schulte, Tim Steimle & Frank Verheyen. 2022. Management im Gesundheitswesen. Management im Gesundheitswesen 11 217 .
Dominik J. Wettstein & Stefan Boes. (2018) Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review. Applied Health Economics and Health Policy 17:2, pages 143-162.
Crossref
David Granlund & Mats A. Bergman. (2018) Price competition in pharmaceuticals – Evidence from 1303 Swedish markets. Journal of Health Economics 61, pages 1-12.
Crossref
Reinhard Busse, Jonas Schreyögg, Oliver Tiemann, Bernhard Gibis, Susanne Weinbrenner, Tom Stargardt, Helmut Hildebrandt, Oliver Gröne, Timo Schulte, Ingo Meyer, Christian Melle, Olga Brüwer, Tim Steimle & Frank Verheyen. 2017. Management im Gesundheitswesen. Management im Gesundheitswesen 11 174 .
Panagiotis Petrou & Sotiris Vandoros. (2015) Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment. Health Policy 119:5, pages 563-568.
Crossref
Michael T. Mueller & Alexander Frenzel. (2013) Competitive pricing within pharmaceutical classes: evidence on “follow-on” drugs in Germany 1993–2008. The European Journal of Health Economics 16:1, pages 73-82.
Crossref
Panagiotis Petrou & Michael A. Talias. (2014) Tendering for pharmaceuticals as a reimbursement tool in the Cyprus Public Health Sector. Health Policy and Technology 3:3, pages 167-175.
Crossref
Sotiris Vandoros. (2014) THERAPEUTIC SUBSTITUTION POST-PATENT EXPIRY: THE CASES OF ACE INHIBITORS AND PROTON PUMP INHIBITORS. Health Economics 23:5, pages 621-630.
Crossref
T. Stargardt & S. Vandoros. 2014. Encyclopedia of Health Economics. Encyclopedia of Health Economics 29 36 .
Gisela Hostenkamp. (2013) Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector. Health Policy 111:1, pages 68-77.
Crossref
Sotiris Vandoros & Tom Stargardt. (2013) Reforms in the Greek pharmaceutical market during the financial crisis. Health Policy 109:1, pages 1-6.
Crossref
Hazel V. J. Moir, Brigitte Tenni, Deborah Helen Gleeson & Ruth Lopert. (2014) Assessing the Impact of Alternative Patent Systems on the Cost of Health Care: The TPPA and HIV Treatment in Vietnam. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.